Abstract
The incidence of systemic fungal infections especially has been growing in last decades. It is related to the expansion of HIV/AIDS pandemic and also to the development of therapy of many diseases that affect immunity.
It has resulted in the development of new drugs and new therapeutic classes, or changes in the administration and indications of formerly known drugs. Moreover, new therapeutic approaches have also been employed in the therapy of topical mycoses, and this article is devoted to them, too.